• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Park Ha Biological Technology Co. Ltd.

    7/10/25 2:00:59 PM ET
    $PHH
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $PHH alert in real time by email
    S-8 1 ea0248250-s8_parkha.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on July 10, 2025

    Registration No. 333-              

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

    Park Ha Biological Technology Co., Ltd.

    (Exact name of registrant as specified in its charter)

      

    Cayman Islands   N/A
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    901, Building C, Phase 2,

    Wuxi International Life Science Innovation Campus

    196 Jinghui East Road

    Xinwu District, Wuxi, Jiangsu Province

    People’s Republic of China

      214000
    (Address of Principal Executive Offices)   (Zip Code)

     

    Amended and Restated 2025 Share Incentive Plan

    (Full title of the plan)

     

    Cogency Global Inc.

    122 East 42nd Street, 18th Floor

    New York, NY 10168

    +1 (212) 947-7200

    (Name, address and telephone number of agent for service)

     

    Copy to:

     

    Kyle Leung, Esq.

    Concord & Sage PC

    1360 Valley Vista Dr Suite 140

    Diamond Bar, CA 91765
    Tel: 929-989-7572

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☐
        Emerging growth company ¨☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    The purpose of this Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an additional 4,500,000 ordinary shares, par value US$0.00002 each (the “Ordinary Shares”) of Park Ha Biological Technology Co., Ltd. (the “Registrant”) reserved for future delivery of shares pursuant to the awards granted or to be granted under the  Registrant’s Amended and Restated 2025 Share Incentive Plan (the “Amended Plan”), which were not previously registered under the registration statements on Form S-8 (File No. 333-285482), as filed with the U.S. Securities and Exchange Commission (the “Commission”) on March 3, 2025 (the “Prior Registration Statements”). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements, are incorporated by reference into this Registration Statement, except that the provisions contained in Part I of the Prior Registration Statements are modified as set forth in this Registration Statement.

     

    On July 7, 2025, the Registrant’s board of directors approved the adoption of the Amended Plan, which amended and restated the Registrant’s 2025 Share Incentive Plan to, among other things, increase the maximum aggregate number of Ordinary Shares that may be issued shall be 7,500,000 Ordinary Shares. The awards granted under the 2025 Share Incentive Plan shall remain valid in accordance with the terms and conditions thereunder.

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information

     

    The Registrant has adopted the Amended Plan. The maximum aggregate number of Ordinary Shares that are available for issuance under the Amended Plan is 7,500,000 Ordinary Shares. This Registration Statement on Form S-8 is being filed with the Commission for the purposes of registering an additional 4,500,000 Ordinary Shares issuable under the Amended Plan.

     

    1 

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents previously filed by the Registrant with the Commission are incorporated by reference herein:

     

      (a) the Registrant’s registration statement on Form S-8 (File No. 333-285482) filed with the Commission on March 3, 2025;

     

      (b) the Registrant’s Annual Report on Form 20-F (File No. 001-42453) for the fiscal year ended October 31, 2024, filed with the Commission on February 24, 2025;

     

      (c) the Registrant’s Current Reports on Form 6-K (File No. 001-42453) filed with the Commission on December 30, 2024, January 7, 2025 and January 24, 2025; and

     

      (d) the description of the Registrant’s Ordinary Shares incorporated by reference in the Registrant’s registration statement on Form 8-A (File No. 001-42453) filed with the Commission on December 26, 2024, including any amendment and report subsequently filed for the purpose of updating that description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement in a document incorporated or deemed to be incorporated by reference in this Registration Statement will be deemed to be modified or superseded to the extent that a statement contained in this Registration Statement or in any other later filed document that also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded will not be deemed, except as so modified or superseded, to be a part of this Registration Statement. 

     

    II-1 

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement:

     

    Exhibit
    Number
      Exhibit Description
    5.1*   Opinion of Ogier with respect to the validity of the securities being registered.
    10.1*   Amended and Restated 2025 Share Incentive Plan.
    23.1*   Consent of WWC, P.C., an independent registered public accounting firm.
    107*   Filing Fee Table.

     

      * Filed herewith.

     

    II-2 

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in China, on July 10, 2025.

     

      Park Ha Biological Technology Co., Ltd.

     

      By: /s/ Xiaoqiu Zhang
        Xiaoqiu Zhang
        Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on July 10, 2025.

     

    Signature   Title
         
    /s/ Xiaoqiu Zhang   Chief Executive Officer and
    Xiaoqiu Zhang   Chairperson of the Board (principal executive officer)
         
    /s/ Xiaoyan Zhu   Chief Financial Officer
    Xiaoyan Zhu   (principal financial officer and principal accounting officer)
         
    /s/ Li Wang    
    Li Wang   Director

     

    /s/ Yanan Shan    
    Yanan Shan   Independent Director
         
    /s/ Qixiong Sheng    
    Qixiong Sheng   Independent Director
         
    /s/ Xiaozhong Yu    
    Xiaozhong Yu   Independent Director
         
    /s/ Da Yang    
    Da Yang   Independent Director

     

    II-3 

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Park Ha Biological Technology Co., Ltd., has signed this registration statement on July 10, 2025.

     

      Concord & Sage PC

     

      By: /s/ Kyle Leung
      Name:   Kyle Leung

     

     

    II-4

     

     

    Get the next $PHH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PHH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PHH
    SEC Filings

    See more
    • SEC Form S-8 filed by Park Ha Biological Technology Co. Ltd.

      S-8 - Park Ha Biological Technology Co., Ltd. (0001986247) (Filer)

      7/10/25 2:00:59 PM ET
      $PHH
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form S-8 filed by Park Ha Biological Technology Co. Ltd.

      S-8 - Park Ha Biological Technology Co., Ltd. (0001986247) (Filer)

      3/3/25 8:30:49 AM ET
      $PHH
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form 20-F filed by Park Ha Biological Technology Co. Ltd.

      20-F - Park Ha Biological Technology Co., Ltd. (0001986247) (Filer)

      2/24/25 4:00:48 PM ET
      $PHH
      Package Goods/Cosmetics
      Consumer Discretionary

    $PHH
    Leadership Updates

    Live Leadership Updates

    See more
    • Open Lending Appoints Veteran Financial Services Executive Massimo Monaco as Chief Financial Officer

      AUSTIN, Texas, July 24, 2025 (GLOBE NEWSWIRE) -- Open Lending Corporation (NASDAQ:LPRO) ("Open Lending" or the "Company"), an industry trailblazer in automotive lending enablement and risk analytics solutions for financial institutions, today announced the appointment of Massimo Monaco as Chief Financial Officer, effective August 18, 2025. Mr. Monaco brings over two decades of executive finance leadership experience in the residential mortgage lending and financial services industries, and he is known for driving change, strengthening financial discipline, and building strong partnerships with internal and external stakeholders. Most recently, he served as Chief Financial Officer of Arc H

      7/24/25 4:05:00 PM ET
      $LPRO
      $PHH
      Finance: Consumer Services
      Finance
      Package Goods/Cosmetics
      Consumer Discretionary

    $PHH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Open Lending Appoints Veteran Financial Services Executive Massimo Monaco as Chief Financial Officer

      AUSTIN, Texas, July 24, 2025 (GLOBE NEWSWIRE) -- Open Lending Corporation (NASDAQ:LPRO) ("Open Lending" or the "Company"), an industry trailblazer in automotive lending enablement and risk analytics solutions for financial institutions, today announced the appointment of Massimo Monaco as Chief Financial Officer, effective August 18, 2025. Mr. Monaco brings over two decades of executive finance leadership experience in the residential mortgage lending and financial services industries, and he is known for driving change, strengthening financial discipline, and building strong partnerships with internal and external stakeholders. Most recently, he served as Chief Financial Officer of Arc H

      7/24/25 4:05:00 PM ET
      $LPRO
      $PHH
      Finance: Consumer Services
      Finance
      Package Goods/Cosmetics
      Consumer Discretionary
    • Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering

      Wuxi, China, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) (the "Company"), a company focused on developing private skincare labels, direct skincare product sales, and franchise alliance promotions, today announced the closing of its initial public offering (the "Offering") of 1,200,000 ordinary shares (the "Ordinary Shares") at a public offering price of $4.00 per ordinary share. The Ordinary Shares began trading on the Nasdaq Capital Market on December 27, 2024 under the ticker symbol "PHH." The Company received aggregate gross proceeds of $4.8 million from the Offering, before deducting underwriting discounts and other related expenses payable b

      12/30/24 5:30:00 PM ET
      $PHH
      Package Goods/Cosmetics
      Consumer Discretionary